Top-Rated StocksTop-RatedNASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free RVMD Stock Alerts $37.38 +0.21 (+0.56%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$36.92▼$37.9850-Day Range$29.94▼$40.2052-Week Range$15.44▼$40.21Volume947,179 shsAverage Volume1.34 million shsMarket Capitalization$6.17 billionP/E RatioN/ADividend YieldN/APrice Target$43.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Revolution Medicines alerts: Email Address Revolution Medicines MarketRank™ Stock AnalysisAnalyst RatingBuy3.10 Rating ScoreUpside/Downside15.6% Upside$43.20 Price TargetShort InterestBearish7.59% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.58Based on 26 Articles This WeekInsider TradingSelling Shares$1.03 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.13) to ($3.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.70 out of 5 starsMedical Sector744th out of 2,771 stocksBiological Products, Except Diagnostic Industry97th out of 462 stocks 3.6 Analyst's Opinion Consensus RatingRevolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRevolution Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revolution Medicines' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.59% of the outstanding shares of Revolution Medicines have been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Revolution Medicines has recently increased by 0.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revolution Medicines is -0.81. Previous Next 2.0 News and Social Media Coverage News SentimentRevolution Medicines has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Revolution Medicines this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,031,049.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revolution Medicines' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Revolution Medicines are expected to decrease in the coming year, from ($3.13) to ($3.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Revolution Medicines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe World’s Richest Man Blindsided by AIThese billionaires know that early investors in AI stand to make a lot of money. The same is true for everyday Americans... including you.Get the full story here. About Revolution Medicines Stock (NASDAQ:RVMD)Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More RVMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVMD Stock News HeadlinesMay 5, 2024 | insidertrades.comJack Anders Sells 10,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) StockMay 13 at 3:57 AM | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Given New $46.00 Price Target at WedbushMay 13 at 2:50 AM | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)May 13 at 1:50 AM | americanbankingnews.comRevolution Medicines, Inc. Forecasted to Post Q2 2024 Earnings of ($0.76) Per Share (NASDAQ:RVMD)May 13 at 1:50 AM | americanbankingnews.comBrokers Issue Forecasts for Revolution Medicines, Inc.'s Q2 2024 Earnings (NASDAQ:RVMD)May 12 at 1:16 AM | americanbankingnews.comAnalyzing Revolution Medicines (NASDAQ:RVMD) and Precision BioSciences (NASDAQ:DTIL)May 10, 2024 | finance.yahoo.comRevolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...May 10, 2024 | finance.yahoo.comRevolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comRevolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 8, 2024 | msn.comRVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024May 8, 2024 | globenewswire.comRevolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate ProgressMay 7, 2024 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Trading Down 4.2% on Insider SellingMay 4, 2024 | finance.yahoo.comInsider Sale: CFO Jack Anders Sells 10,000 Shares of Revolution Medicines Inc (RVMD)May 1, 2024 | globenewswire.comRevolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024April 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - RVMDApril 17, 2024 | msn.comRevolution Medicines (RVMD) Price Target Increased by 5.15% to 41.65April 15, 2024 | investing.comRevolution Medicines executive sells over $619k in company stockApril 14, 2024 | investing.comRevolution Medicines director sells shares worth $79,735April 12, 2024 | markets.businessinsider.comBuy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer TherapiesApril 11, 2024 | uk.investing.comRevolution Medicines reports progress in RAS cancer therapyApril 10, 2024 | msn.comWhat's Going On With Revolution Medicines Stock?April 10, 2024 | uk.investing.comRevolution Medicines reports breakthrough in RAS-mutant cancer treatmentApril 9, 2024 | globenewswire.comRevolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsApril 8, 2024 | markets.businessinsider.comRevolution Medicines’ Robust Cancer Drug Pipeline Justifies Buy RatingApril 8, 2024 | globenewswire.comRevolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsSee More Headlines Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:RVMD CUSIPN/A CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees378Year FoundedN/APrice Target and Rating Average Stock Price Target$43.20 High Stock Price Target$48.00 Low Stock Price Target$34.00 Potential Upside/Downside+15.6%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-436,370,000.00 Net MarginsN/A Pretax Margin-10,683.22% Return on Equity-36.41% Return on Assets-32.13% Debt Debt-to-Equity RatioN/A Current Ratio18.45 Quick Ratio18.45 Sales & Book Value Annual Sales$11.58 million Price / Sales532.58 Cash FlowN/A Price / Cash FlowN/A Book Value$11.09 per share Price / Book3.37Miscellaneous Outstanding Shares164,990,000Free Float150,962,000Market Cap$6.17 billion OptionableOptionable Beta1.46 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Mark A. Goldsmith Ph.D. (Age 62)CEO, President & Chairman Comp: $1.12MMr. Jack Anders (Age 47)Chief Financial Officer Comp: $665.28kMs. Margaret A. Horn J.D. (Age 61)Chief Operating Officer Comp: $811.08kDr. Stephen M. Kelsey FRC Path. (Age 63)FRCP, M.D., President of Research & Development Comp: $812.17kMs. Xiaolin Wang (Age 53)Executive Vice President of Development Comp: $633.74kDr. Martin D. Burke M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardDr. Michael A. Fischbach Ph.D. (Age 43)Academic Co-Founder & Member of Scientific Advisory Board Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerMs. Jan Smith Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsExelixisNASDAQ:EXELVaxcyteNASDAQ:PCVXImmunityBioNASDAQ:IBRXHalozyme TherapeuticsNASDAQ:HALOCRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsAmerican International Group Inc.Sold 2,750 shares on 5/14/2024Ownership: 0.042%CANADA LIFE ASSURANCE CoBought 6,696 shares on 5/14/2024Ownership: 0.009%NatixisBought 6,075 shares on 5/14/2024Ownership: 0.004%EntryPoint Capital LLCBought 3,335 shares on 5/14/2024Ownership: 0.002%Ameritas Investment Partners Inc.Sold 978 shares on 5/13/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions RVMD Stock Analysis - Frequently Asked Questions Should I buy or sell Revolution Medicines stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVMD shares. View RVMD analyst ratings or view top-rated stocks. What is Revolution Medicines' stock price target for 2024? 10 equities research analysts have issued 12-month price objectives for Revolution Medicines' shares. Their RVMD share price targets range from $34.00 to $48.00. On average, they predict the company's share price to reach $43.20 in the next year. This suggests a possible upside of 15.6% from the stock's current price. View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts. How have RVMD shares performed in 2024? Revolution Medicines' stock was trading at $28.68 at the beginning of 2024. Since then, RVMD stock has increased by 30.3% and is now trading at $37.38. View the best growth stocks for 2024 here. When is Revolution Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our RVMD earnings forecast. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) released its earnings results on Wednesday, May, 8th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.05. The firm's revenue for the quarter was down 100.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.72) EPS. What ETFs hold Revolution Medicines' stock? ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Tema Oncology ETF (CANC), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL). When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $150 million in an IPO on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.66%), Mass General Brigham Inc (0.21%), Susquehanna Fundamental Investments LLC (0.12%), American International Group Inc. (0.04%), Seven Eight Capital LP (0.04%) and Mirae Asset Global Investments Co. Ltd. (0.03%). Insiders that own company stock include Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Sushil Patel, Thilo Schroeder and Xiaolin Wang. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVMD) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsAmerica’s worst nightmare?Porter & CompanyCrypto Millionaire Says: “Buy This $11 AI Coin.”InvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
